Clinical Trial Update: A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) [Phase 3]

View source ↗

Summary

Phase 3 study of VX-659 combination therapy in CF patients with F508del and minimal function mutation completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-659 (VX-659)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2020-03-13